Denali Therapeutics, Inc. (DNLI)
18.34
+0.47
(+2.63%)
USD |
NASDAQ |
Oct 15, 16:00
18.40
+0.06
(+0.33%)
After-Hours: 20:00
Denali Therapeutics Cash from Operations (TTM) : -434.04M for June 30, 2026
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -434.04M |
| March 31, 2026 | -412.34M |
| December 31, 2025 | -412.60M |
| September 30, 2025 | -397.78M |
| June 30, 2025 | -349.62M |
| March 31, 2025 | -365.54M |
| December 31, 2024 | -347.69M |
| September 30, 2024 | -362.64M |
| June 30, 2024 | -390.86M |
| March 31, 2024 | -412.81M |
| December 31, 2023 | -357.99M |
| September 30, 2023 | -332.00M |
| June 30, 2023 | -301.68M |
| March 31, 2023 | -231.41M |
| December 31, 2022 | -244.72M |
| September 30, 2022 | -237.55M |
| Date | Value |
|---|---|
| June 30, 2022 | -221.94M |
| March 31, 2022 | -233.26M |
| December 31, 2021 | -211.39M |
| September 30, 2021 | 368.02M |
| June 30, 2021 | 409.54M |
| March 31, 2021 | 420.40M |
| December 31, 2020 | 416.15M |
| September 30, 2020 | -145.41M |
| June 30, 2020 | -175.93M |
| March 31, 2020 | -175.74M |
| December 31, 2019 | -151.58M |
| September 30, 2019 | -10.75M |
| June 30, 2019 | -15.14M |
| March 31, 2019 | -13.78M |
| December 31, 2018 | 50.12M |
| September 30, 2018 | -61.40M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -59.06M |
| Oncolytics Biotech, Inc. | -26.52M |
| Sangamo Therapeutics, Inc. | -90.34M |
| Sarepta Therapeutics, Inc. | 93.95M |
| Anixa Biosciences, Inc. | -7.376M |